{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:19:08Z","timestamp":1790176748350,"version":"4.1.0"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,8,23]],"date-time":"2014-08-23T00:00:00Z","timestamp":1408752000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s10096-014-2208-6","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T15:07:00Z","timestamp":1414681620000},"page":"19-31","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?"],"prefix":"10.1007","volume":"34","author":[{"given":"A.","family":"Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hryniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moutschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. R.","family":"Reinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Welte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,23]]},"reference":[{"issue":"Suppl 1","key":"2208_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00002512-199915001-00002","volume":"15","author":"JC Butler","year":"1999","unstructured":"Butler JC, Schuchat A (1999) Epidemiology of pneumococcal infections in the elderly. Drugs Aging 15(Suppl 1):11\u201319","journal-title":"Drugs Aging"},{"key":"2208_CR2","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1016\/j.vaccine.2014.04.066","volume":"32","author":"AN Torn\u00e9","year":"2014","unstructured":"Torn\u00e9 AN, Dias JG, Quinten C, Hruba F, Busana MC, Lopalco PL, Gauci AJ, Pastore-Celentano L; ECDC country experts for pneumococcal disease (2014) European enhanced surveillance of invasive pneumococcal disease in 2010: data from 26 European countries in the post-heptavalent conjugate vaccine era. Vaccine 32:3644\u20133650","journal-title":"Vaccine"},{"key":"2208_CR3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MD.0b013e3181f2b824","volume":"89","author":"AM Rueda","year":"2010","unstructured":"Rueda AM, Serpa JA, Matloobi M, Mushtaq M, Musher DM (2010) The spectrum of invasive pneumococcal disease at an adult tertiary care hospital in the early 21st century. Medicine (Baltimore) 89:331\u2013336","journal-title":"Medicine (Baltimore)"},{"key":"2208_CR4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1183\/09059180.00000312","volume":"21","author":"T Welte","year":"2012","unstructured":"Welte T (2012) How can we reduce the mortality of invasive pneumococcal disease? Eur Respir Rev 21:6\u20137","journal-title":"Eur Respir Rev"},{"key":"2208_CR5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","volume":"374","author":"KL O\u2019Brien","year":"2009","unstructured":"O\u2019Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T; Hib and Pneumococcal Global Burden of Disease Study Team (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374:893\u2013902","journal-title":"Lancet"},{"key":"2208_CR6","doi-asserted-by":"crossref","unstructured":"Jansen AG, Rodenburg GD, de Greeff SC, Hak E, Veenhoven RH, Spanjaard L, Schouls LM, Sanders EA, van der Ende A (2009) Invasive pneumococcal disease in the Netherlands: syndromes, outcome and potential vaccine benefits. Vaccine 27:2394\u20132401","DOI":"10.1016\/j.vaccine.2009.01.127"},{"key":"2208_CR7","unstructured":"Torres A, Rodr\u00edguez-Cr\u00e9ixems M, Grau I, Molinos L, Llinares P, De la Cruz JL, Rajas O, Alfageme I, Salavert M, Fenoll A, Li\u00f1ares J, Cifuentes I (2013) Underlying clinical conditions and invasive pneumococcal disease (IPD) in adults in Spain (ODIN study, 2010\u20132012). Abstract 5051. European Respiratory Society (ERS) Annual Congress 2013, Barcelona, Spain, 7\u201311 September 2013. Available online at: http:\/\/www.ers-education.org\/events\/annual-congress.aspx?idParent=125517 . Accessed 12 August 2014"},{"key":"2208_CR8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jinf.2012.02.017","volume":"65","author":"AJ Hoek van","year":"2012","unstructured":"van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, Miller E (2012) The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 65:17\u201324","journal-title":"J Infect"},{"key":"2208_CR9","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","volume":"348","author":"CG Whitney","year":"2003","unstructured":"Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A; Active Bacterial Core Surveillance of the Emerging Infections Program Network (2003) Decline in invasive pneumococcal disease after the introduction of protein\u2013polysaccharide conjugate vaccine. N Engl J Med 348:1737\u20131746","journal-title":"N Engl J Med"},{"key":"2208_CR10","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1001\/jama.295.14.1668","volume":"295","author":"KA Poehling","year":"2006","unstructured":"Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, Lexau CA, Thomas AR, Harrison LH, Reingold AL, Hadler JL, Farley MM, Anderson BJ, Schaffner W (2006) Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 295:1668\u20131674","journal-title":"JAMA"},{"key":"2208_CR11","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/j.ijid.2009.05.010","volume":"14","author":"DJ Isaacman","year":"2010","unstructured":"Isaacman DJ, McIntosh ED, Reinert RR (2010) Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 14:e197\u2013e209","journal-title":"Int J Infect Dis"},{"key":"2208_CR12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/ijcp.12234","volume":"68","author":"MA Rose","year":"2014","unstructured":"Rose MA, Christopoulou D, Myint TT, de Schutter I (2014) The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe. Int J Clin Pract 68:8\u201319","journal-title":"Int J Clin Pract"},{"key":"2208_CR13","unstructured":"Nuorti JP (2000) Epidemiology of invasive pneumococcal disease in adults: implications for prevention. National Public Health Institute, Helsinki, Finland. Available online at: http:\/\/ethesis.helsinki.fi\/julkaisut\/laa\/kliin\/vk\/nuorti\/epidemio.pdf . Accessed 12 August 2014"},{"key":"2208_CR14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/0003-4819-150-1-200901060-00008","volume":"150","author":"Advisory Committee on Immunization Practices","year":"2009","unstructured":"Advisory Committee on Immunization Practices (2009) Recommended adult immunization schedule: United States, 2009. Ann Intern Med 150:40\u201344","journal-title":"Ann Intern Med"},{"key":"2208_CR15","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/rheumatology\/keq183","volume":"49","author":"JF Rahier","year":"2010","unstructured":"Rahier JF, Moutschen M, Van Gompel A, Van Ranst M, Louis E, Segaert S, Masson P, De Keyser F (2010) Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 49:1815\u20131827","journal-title":"Rheumatology (Oxford)"},{"key":"2208_CR16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.vaccine.2010.11.025","volume":"29","author":"R Gil-Prieto","year":"2011","unstructured":"Gil-Prieto R, Garc\u00eda-Garc\u00eda L, Alvaro-Meca A, M\u00e9ndez C, Garc\u00eda A, de Miguel AG (2011) The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003\u20132007). Vaccine 29:412\u2013416","journal-title":"Vaccine"},{"key":"2208_CR17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","volume":"67","author":"T Welte","year":"2012","unstructured":"Welte T, Torres A, Nathwani D (2012) Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67:71\u201379","journal-title":"Thorax"},{"key":"2208_CR18","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/thoraxjnl-2013-204282","volume":"68","author":"A Torres","year":"2013","unstructured":"Torres A, Peetermans WE, Viegi G, Blasi F (2013) Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 68:1057\u20131065","journal-title":"Thorax"},{"key":"2208_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0140-6736(01)56370-9","volume":"183","author":"AE Wright","year":"1914","unstructured":"Wright AE, Morgan WP, Colebrook L, Dodgson RW (1914) Observations on prophylactic inoculation against pneumococcus infections, and on the results which have been achieved by it. Lancet 183:1\u201310","journal-title":"Lancet"},{"key":"2208_CR20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1586\/erv.10.6","volume":"9","author":"RR Reinert","year":"2010","unstructured":"Reinert RR, Paradiso P, Fritzell B (2010) Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev Vaccines 9:229\u2013236","journal-title":"Expert Rev Vaccines"},{"key":"2208_CR21","first-page":"308","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","unstructured":"Centers for Disease Control and Prevention (CDC) (2013) Progress in introduction of pneumococcal conjugate vaccine\u2014worldwide, 2000\u20132012. MMWR Morb Mortal Wkly Rep 62:308\u2013311","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2208_CR22","unstructured":"GlaxoSmithKline Biologicals s.a. (2014) Synoflorix: summary of product characteristics. European Medicines Agency (EMA). Available online at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000973\/WC500054346.pdf . Accessed 12 August 2014"},{"key":"2208_CR23","unstructured":"electronic Medicines Compendium (eMC) (2014) Prevenar 13 suspension for injection. eMC. Available online at: http:\/\/www.medicines.org.uk\/emc\/medicine\/22689\/SPC\/Prevenar+13+suspension+for+injection\/ . Accessed 12 August 2014"},{"key":"2208_CR24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1586\/erv.11.14","volume":"10","author":"G Blanchard-Rohner","year":"2011","unstructured":"Blanchard-Rohner G, Pollard AJ (2011) Long-term protection after immunization with protein\u2013polysaccharide conjugate vaccines in infancy. Expert Rev Vaccines 10:673\u2013684","journal-title":"Expert Rev Vaccines"},{"key":"2208_CR25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/newbio245012a0","volume":"245","author":"A Coutinho","year":"1973","unstructured":"Coutinho A, M\u00f6ller G (1973) B cell mitogenic properties of thymus-independent antigens. Nat New Biol 245:12\u201314","journal-title":"Nat New Biol"},{"key":"2208_CR26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0065-3101(24)00217-2","volume":"32","author":"DJ Barrett","year":"1985","unstructured":"Barrett DJ (1985) Human immune responses to polysaccharide antigens: an analysis of bacterial polysaccharide vaccines in infants. Adv Pediatr 32:139\u2013158","journal-title":"Adv Pediatr"},{"key":"2208_CR27","first-page":"127","volume":"63","author":"DJ Barrett","year":"1986","unstructured":"Barrett DJ, Ayoub EM (1986) IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol 63:127\u2013134","journal-title":"Clin Exp Immunol"},{"key":"2208_CR28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1084\/jem.20011112","volume":"195","author":"KM Toellner","year":"2002","unstructured":"Toellner KM, Jenkinson WE, Taylor DR, Khan M, Sze DM, Sansom DM, Vinuesa CG, MacLennan IC (2002) Low-level hypermutation in T cell-independent germinal centers compared with high mutation rates associated with T cell-dependent germinal centers. J Exp Med 195:383\u2013389","journal-title":"J Exp Med"},{"key":"2208_CR29","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1182\/blood-2009-01-200014","volume":"114","author":"M Taillardet","year":"2009","unstructured":"Taillardet M, Haffar G, Mondi\u00e8re P, Asensio MJ, Gheit H, Burdin N, Defrance T, Genestier L (2009) The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells. Blood 114:4432\u20134440","journal-title":"Blood"},{"key":"2208_CR30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1084\/jem.20052036","volume":"203","author":"TV Obukhanych","year":"2006","unstructured":"Obukhanych TV, Nussenzweig MC (2006) T-independent type II immune responses generate memory B cells. J Exp Med 203:305\u2013310","journal-title":"J Exp Med"},{"key":"2208_CR31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1074-7613(01)00129-7","volume":"14","author":"F Martin","year":"2001","unstructured":"Martin F, Oliver AM, Kearney JF (2001) Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 14:617\u2013629","journal-title":"Immunity"},{"key":"2208_CR32","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.4049\/jimmunol.1001271","volume":"186","author":"SZ Birjandi","year":"2011","unstructured":"Birjandi SZ, Ippolito JA, Ramadorai AK, Witte PL (2011) Alterations in marginal zone macrophages and marginal zone B cells in old mice. J Immunol 186:3441\u20133451","journal-title":"J Immunol"},{"key":"2208_CR33","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.1182\/blood-2010-05-284547","volume":"116","author":"L Tortola","year":"2010","unstructured":"Tortola L, Yadava K, Bachmann MF, M\u00fcller C, Kisielow J, Kopf M (2010) IL-21 induces death of marginal zone B cells during chronic inflammation. Blood 116:5200\u20135207","journal-title":"Blood"},{"key":"2208_CR34","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1084\/jem.20022020","volume":"197","author":"S Kruetzmann","year":"2003","unstructured":"Kruetzmann S, Rosado MM, Weber H, Germing U, Tournilhac O, Peter HH, Berner R, Peters A, Boehm T, Plebani A, Quinti I, Carsetti R (2003) Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 197:939\u2013945","journal-title":"J Exp Med"},{"key":"2208_CR35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0046-8177(03)00422-2","volume":"35","author":"C Kruschinski","year":"2004","unstructured":"Kruschinski C, Zidan M, Debertin AS, von H\u00f6rsten S, Pabst R (2004) Age-dependent development of the splenic marginal zone in human infants is associated with different causes of death. Hum Pathol 35:113\u2013121","journal-title":"Hum Pathol"},{"key":"2208_CR36","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.4049\/jimmunol.125.4.1499","volume":"125","author":"PH Brodeur","year":"1980","unstructured":"Brodeur PH, Wortis HH (1980) Regulation of thymus-independent responses: unresponsiveness to a second challenge of TNP-Ficoll is mediated by hapten-specific antibodies. J Immunol 125:1499\u20131505","journal-title":"J Immunol"},{"key":"2208_CR37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","volume":"9","author":"AJ Pollard","year":"2009","unstructured":"Pollard AJ, Perrett KP, Beverley PC (2009) Maintaining protection against invasive bacteria with protein\u2013polysaccharide conjugate vaccines. Nat Rev Immunol 9:213\u2013220","journal-title":"Nat Rev Immunol"},{"key":"2208_CR38","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/infdis\/jir750","volume":"205","author":"SF Brynjolfsson","year":"2012","unstructured":"Brynjolfsson SF, Henneken M, Bjarnarson SP, Mori E, Del Giudice G, Jonsdottir I (2012) Hyporesponsiveness following booster immunization with bacterial polysaccharides is caused by apoptosis of memory B cells. J Infect Dis 205:422\u2013430","journal-title":"J Infect Dis"},{"key":"2208_CR39","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.4049\/jimmunol.1002976","volume":"186","author":"S Kanswal","year":"2011","unstructured":"Kanswal S, Katsenelson N, Allman W, Uslu K, Blake MS, Akkoyunlu M (2011) Suppressive effect of bacterial polysaccharides on BAFF system is responsible for their poor immunogenicity. J Immunol 186:2430\u20132443","journal-title":"J Immunol"},{"key":"2208_CR40","doi-asserted-by":"crossref","first-page":"659","DOI":"10.4049\/jimmunol.163.2.659","volume":"163","author":"ZQ Wu","year":"1999","unstructured":"Wu ZQ, Vos Q, Shen Y, Lees A, Wilson SR, Briles DE, Gause WC, Mond JJ, Snapper CM (1999) In vivo polysaccharide-specific IgG isotype responses to intact Streptococcus pneumoniae are T cell dependent and require CD40- and B7-ligand interactions. J Immunol 163:659\u2013667","journal-title":"J Immunol"},{"key":"2208_CR41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1146\/annurev.iy.12.040194.001001","volume":"12","author":"IC MacLennan","year":"1994","unstructured":"MacLennan IC (1994) Germinal centers. Annu Rev Immunol 12:117\u2013139","journal-title":"Annu Rev Immunol"},{"key":"2208_CR42","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/nm.2535","volume":"17","author":"FY Avci","year":"2011","unstructured":"Avci FY, Li X, Tsuji M, Kasper DL (2011) A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med 17:1602\u20131609","journal-title":"Nat Med"},{"key":"2208_CR43","first-page":"144","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","unstructured":"Centers for Disease Control and Prevention (CDC) (2008) Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction\u2014eight states, 1998\u20132005. MMWR Morb Mortal Wkly Rep 57:144\u2013148","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2208_CR44","first-page":"18","volume":"32","author":"PW Roche","year":"2008","unstructured":"Roche PW, Krause V, Cook H, Barralet J, Coleman D, Sweeny A, Fielding J, Giele C, Gilmour R, Holland R, Kampen R; Enhanced Invasive Pneumococcal Disease Surveillance Working Group, Brown M, Gilbert L, Hogg G, Murphy D; Pneumococcal Working Party of the Communicable Diseases Network Australia (2008) Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell Q Rep 32:18\u201330","journal-title":"Commun Dis Intell Q Rep"},{"key":"2208_CR45","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1503\/cmaj.051150","volume":"173","author":"JD Kellner","year":"2005","unstructured":"Kellner JD, Church DL, MacDonald J, Tyrrell GJ, Scheifele D (2005) Progress in the prevention of pneumococcal infection. CMAJ 173:1149\u20131151","journal-title":"CMAJ"},{"key":"2208_CR46","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/adc.2007.119891","volume":"92","author":"F Dubos","year":"2007","unstructured":"Dubos F, Marechal I, Husson MO, Courouble C, Aurel M, Martinot A; Hospital Network for Evaluating the Management of Common Childhood Diseases (2007) Decline in pneumococcal meningitis after the introduction of the heptavalent-pneumococcal conjugate vaccine in northern France. Arch Dis Child 92:1009\u20131012","journal-title":"Arch Dis Child"},{"key":"2208_CR47","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1016\/j.vaccine.2009.04.057","volume":"27","author":"S R\u00fcckinger","year":"2009","unstructured":"R\u00fcckinger S, van der Linden M, Reinert RR, von Kries R, Burckhardt F, Siedler A (2009) Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 27:4136\u20134141","journal-title":"Vaccine"},{"key":"2208_CR48","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/j.vaccine.2008.03.087","volume":"26","author":"DF Vestrheim","year":"2008","unstructured":"Vestrheim DF, L\u00f8voll O, Aaberge IS, Caugant DA, H\u00f8iby EA, Bakke H, Bergsaker MR (2008) Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26:3277\u20133281","journal-title":"Vaccine"},{"key":"2208_CR49","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10096-008-0693-1","volume":"28","author":"E P\u00e9rez-Trallero","year":"2009","unstructured":"P\u00e9rez-Trallero E, Marimon JM, Ercibengoa M, Vicente D, P\u00e9rez-Yarza EG (2009) Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis 28:731\u2013738","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2208_CR50","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(07)60564-9","volume":"369","author":"CG Grijalva","year":"2007","unstructured":"Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR (2007) Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369:1179\u20131186","journal-title":"Lancet"},{"key":"2208_CR51","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10096-010-0928-9","volume":"29","author":"M Patrza\u0142ek","year":"2010","unstructured":"Patrza\u0142ek M, Albrecht P, Sobczynski M (2010) Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland. Eur J Clin Microbiol Infect Dis 29:787\u2013792","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2208_CR52","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1542\/peds.2006-2138","volume":"119","author":"KA Poehling","year":"2007","unstructured":"Poehling KA, Szilagyi PG, Grijalva CG, Martin SW, LaFleur B, Mitchel E, Barth RD, Nuorti JP, Griffin MR (2007) Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 119:707\u2013715","journal-title":"Pediatrics"},{"key":"2208_CR53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1542\/peds.2007-0619","volume":"121","author":"F Zhou","year":"2008","unstructured":"Zhou F, Shefer A, Kong Y, Nuorti JP (2008) Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997\u20132004. Pediatrics 121:253\u2013260","journal-title":"Pediatrics"},{"key":"2208_CR54","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa051642","volume":"354","author":"MH Kyaw","year":"2006","unstructured":"Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG; Active Bacterial Core Surveillance of the Emerging Infections Program Network (2006) Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354:1455\u20131463","journal-title":"N Engl J Med"},{"key":"2208_CR55","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/521833","volume":"196","author":"KL O\u2019Brien","year":"2007","unstructured":"O\u2019Brien KL, Millar EV, Zell ER, Bronsdon M, Weatherholtz R, Reid R, Becenti J, Kvamme S, Whitney CG, Santosham M (2007) Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis 196:1211\u20131220","journal-title":"J Infect Dis"},{"key":"2208_CR56","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/INF.0b013e318168d28a","volume":"27","author":"IN Grivea","year":"2008","unstructured":"Grivea IN, Panagiotou M, Tsantouli AG, Syrogiannopoulos GA (2008) Impact of heptavalent pneumococcal conjugate vaccine on nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among day-care center attendees in central Greece. Pediatr Infect Dis J 27:519\u2013525","journal-title":"Pediatr Infect Dis J"},{"key":"2208_CR57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.vaccine.2013.05.005","volume":"32","author":"SM Davis","year":"2013","unstructured":"Davis SM, Deloria-Knoll M, Kassa HT, O\u2019Brien KL (2013) Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine 32:133\u2013145","journal-title":"Vaccine"},{"key":"2208_CR58","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1086\/516779","volume":"44","author":"A Barricarte","year":"2007","unstructured":"Barricarte A, Castilla J, Gil-Setas A, Torroba L, Navarro-Alonso JA, Irisarri F, Arriazu M (2007) Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case\u2013control study. Clin Infect Dis 44:1436\u20131441","journal-title":"Clin Infect Dis"},{"key":"2208_CR59","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.arcped.2006.12.010","volume":"14","author":"H Bekri","year":"2007","unstructured":"Bekri H, Cohen R, Varon E, Madhi F, Gire R, Guillot F, Delacourt C (2007) Streptococcus pneumoniae serotypes involved in children with pleural empyemas in France. Arch Pediatr 14:239\u2013243","journal-title":"Arch Pediatr"},{"key":"2208_CR60","unstructured":"Public Health England (2013) Current Epidemiology of Invasive Pneumococcal Disease (IPD). Public Health England. Available online at: http:\/\/www.hpa.org.uk\/Topics\/InfectiousDiseases\/InfectionsAZ\/Pneumococcal\/EpidemiologicalDataPneumococcal\/CurrentEpidemiologyPneumococcal\/ . Accessed 14 May 2013"},{"key":"2208_CR61","unstructured":"van der Linden M, von Kries R, Im\u00f6hl M (2012) Effects of three years of immunization with higher valent pneumococcal conjugate vaccines on serotype distributions among reported IPD cases in German children and adults. Presented at the 52nd ICAAC, September 9\u201312, 2012, San Francisco, CA, USA. Available online at: http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=becf1b8c-545a-4792-ac02-4a9cb31fdf7b&cKey=bb809851-e003-4b87-8957-043e6ed60add&mKey=%7b6B114A1D-85A4-4054-A83B-04D8B9B8749F%7d . Accessed 12 August 2014"},{"key":"2208_CR62","unstructured":"F\u00e9lix S, Valente C, Tavares DA, Nunes S, Brito-Av\u00f4 A, de Lencastre H, S\u00e1-Le\u00e3o R (2012) Temporal trends of serotypes included in the novel 13-valent pneumococcal conjugate vaccine (PCV13) among young children from Portugal. Presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases, Igua\u00e7u Falls, Brazil, March 11\u201315, 2012. Available online at: http:\/\/www2.kenes.com\/ISPPD\/Scientific\/Documents\/FinalAbstractbook.pdf . Accessed 12 August 2014"},{"key":"2208_CR63","unstructured":"Cohen R, Levy C, Bingen E, Bonnet E, Koskas M, Attal S, Nave I, Fritzell B, Varon E (2011) Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on nasopharyngeal (NP) flora in children with acute otitis media (AOM). Presented at the 51st ICAAC, September 17\u201320, 2011, Chicago, USA. Available online at: http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=b0b69d8d-27d1-43f4-8f4e-9b651a2028f3&cKey=a8db6616-5ef8-484f-b65e-4e1d48fcfdac&mKey=0C918954-D607-46A7-8073-44F4B537A439 . Accessed 12 August 2014"},{"key":"2208_CR64","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM200003093421002","volume":"342","author":"JP Nuorti","year":"2000","unstructured":"Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, Breiman RF (2000) Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 342:681\u2013689","journal-title":"N Engl J Med"},{"key":"2208_CR65","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1016\/j.vaccine.2013.10.032","volume":"31","author":"A Steens","year":"2013","unstructured":"Steens A, Bergsaker MA, Aaberge IS, R\u00f8nning K, Vestrheim DF (2013) Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 31:6232\u20136238","journal-title":"Vaccine"},{"key":"2208_CR66","unstructured":"Norwegian Institute of Public Health (2013) Vaccination statistics for 2012\u201495 per cent of 9-year-olds are vaccinated. Norwegian Institute of Public Health. Available online at: http:\/\/www.fhi.no\/artikler\/?id=105667 . Accessed 12 August 2014"},{"key":"2208_CR67","unstructured":"van der Linden M, Imohl M (2013) Serotype distribution and vaccine coverage among pneumococcal disease in adults in Germany [Poster eP737]. Presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Berlin, Germany, 27\u201330 April 2013. Available online at: https:\/\/www.escmid.org\/escmid_library\/online_lecture_library\/?search=1&current_page=1&search_term=Linden&entrytype%5B%5D=18&entrytype%5B%5D=20&entrytype%5B%5D=17&entrytype%5B%5D=19&entrytitle%5B%5D=4534 . Accessed 12 August 2014"},{"key":"2208_CR68","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0140-6736(12)61854-6","volume":"381","author":"AA Palmu","year":"2013","unstructured":"Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, Schuerman L, Kilpi TM (2013) Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 381:214\u2013222","journal-title":"Lancet"},{"key":"2208_CR69","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1016\/j.vaccine.2013.04.007","volume":"31","author":"GH Lim","year":"2013","unstructured":"Lim GH, Wormsbecker AE, McGeer A, Pillai DR, Gubbay JB, Rudnick W, Low DE, Green K, Crowcroft NS, Deeks SL (2013) Have changing pneumococcal vaccination programmes impacted disease in Ontario? Vaccine 31:2680\u20132685","journal-title":"Vaccine"},{"key":"2208_CR70","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3201\/eid1904.121198","volume":"19","author":"ET Afonso","year":"2013","unstructured":"Afonso ET, Minamisava R, Bierrenbach AL, Escalante JJ, Alencar AP, Domingues CM, Morais-Neto OL, Toscano CM, Andrade AL (2013) Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerg Infect Dis 19:589\u2013597","journal-title":"Emerg Infect Dis"},{"key":"2208_CR71","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1097\/INF.0b013e31821a0614","volume":"30","author":"MR Bergh van den","year":"2011","unstructured":"van den Bergh MR, Spijkerman J, Fran\u00e7ois N, Swinnen K, Borys D, Schuerman L, Veenhoven RH, Sanders EA (2011) Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial. Pediatr Infect Dis J 30:e170\u2013e178","journal-title":"Pediatr Infect Dis J"},{"key":"2208_CR72","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/INF.0b013e318199f8ef","volume":"28","author":"T Vesikari","year":"2009","unstructured":"Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Ars\u00e8ne JP, Lommel P, Dieussaert I, Schuerman L (2009) Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 28:S66\u2013S76","journal-title":"Pediatr Infect Dis J"},{"key":"2208_CR73","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/INF.0b013e318199f901","volume":"28","author":"N Bermal","year":"2009","unstructured":"Bermal N, Szenborn L, Chrobot A, Alberto E, Lommel P, Gatchalian S, Dieussaert I, Schuerman L (2009) The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV\/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J 28:S89\u2013S96","journal-title":"Pediatr Infect Dis J"},{"key":"2208_CR74","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1186\/1471-2458-11-882","volume":"11","author":"A Dicko","year":"2011","unstructured":"Dicko A, Odusanya OO, Diallo AI, Santara G, Barry A, Dolo A, Diallo A, Kuyinu YA, Kehinde OA, Fran\u00e7ois N, Borys D, Yarzabal JP, Moreira M, Schuerman L (2011) Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial. BMC Public Health 11:882","journal-title":"BMC Public Health"},{"key":"2208_CR75","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4161\/hv.7.11.17984","volume":"7","author":"GM Ruiz-Palacios","year":"2011","unstructured":"Ruiz-Palacios GM, Guerrero ML, Hern\u00e1ndez-Delgado L, Lavalle-Villalobos A, Casas-Mu\u00f1oz A, Cervantes-Apolinar Y, Moreira M, Schuerman L (2011) Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants. Hum Vaccine 7:1137\u20131145","journal-title":"Hum Vaccine"},{"key":"2208_CR76","doi-asserted-by":"crossref","first-page":"e85459","DOI":"10.1371\/journal.pone.0085459","volume":"9","author":"LL Hammitt","year":"2014","unstructured":"Hammitt LL, Ojal J, Bashraheil M, Morpeth SC, Karani A, Habib A, Borys D, Goldblatt D, Scott JA (2014) Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1\u20134 years: a randomized controlled trial. PLoS One 9:e85459","journal-title":"PLoS One"},{"key":"2208_CR77","unstructured":"Sanofi Pasteur MSD (2014) Pneumovax 23: summary of product characteristics. eMC. Available online at: http:\/\/www.medicines.org.uk\/emc\/medicine\/1446 . Accessed 12 August 2014"},{"key":"2208_CR78","doi-asserted-by":"crossref","unstructured":"Moberley S, Holden J, Tatham DP, Andrews RM (2013) Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 1:CD000422","DOI":"10.1002\/14651858.CD000422.pub3"},{"key":"2208_CR79","first-page":"129","volume":"87","author":"World Health Organization (WHO)","year":"2012","unstructured":"World Health Organization (WHO) (2012) Pneumococcal vaccines WHO position paper\u20142012. Wkly Epidemiol Rec 87:129\u2013144","journal-title":"Wkly Epidemiol Rec"},{"key":"2208_CR80","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(00)02377-1","volume":"355","author":"N French","year":"2000","unstructured":"French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, Moore M, Antvelink D, Mulder D, Janoff EN, Whitworth J, Gilks CF (2000) 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 355:2106\u20132111","journal-title":"Lancet"},{"key":"2208_CR81","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJMoa0903029","volume":"362","author":"N French","year":"2010","unstructured":"French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, Mwaiponya M, Zijlstra EE, Molyneux ME, Gilks CF (2010) A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 362:812\u2013822","journal-title":"N Engl J Med"},{"key":"2208_CR82","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","volume":"31","author":"LA Jackson","year":"2013","unstructured":"Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B (2013) Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 31:3577\u20133584","journal-title":"Vaccine"},{"key":"2208_CR83","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1016\/j.vaccine.2013.05.010","volume":"31","author":"LA Jackson","year":"2013","unstructured":"Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B (2013) Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 31:3585\u20133593","journal-title":"Vaccine"},{"key":"2208_CR84","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1016\/j.vaccine.2013.04.084","volume":"31","author":"LA Jackson","year":"2013","unstructured":"Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B (2013) Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 31:3594\u20133602","journal-title":"Vaccine"},{"key":"2208_CR85","unstructured":"Schmoele-Thoma A, Jackson LA, Greenberg RN, Frenck R, Gurtman A, Jayawardene D, Emini EA, Gruber W, Scott, DA (2012) The immunogenicity of Prevnar 13 in immunocompetent older adults with stable high risk conditions is comparable to that in healthy older adults. Presented at IDWeek 2012, San Diego, CA, October 17\u201321, 2012. Available online at: https:\/\/idsa.confex.com\/idsa\/2012\/webprogram\/Paper36522.html . Accessed 12 August 2014"},{"key":"2208_CR86","unstructured":"Frenck R Jr, Thompson A, Senders S, Patterson S, Devlin C, Jansen K, Gruber WC, Emini EA, Scott DA, Gurtman A (2012) 13-valent pneumococcal conjugate vaccine in older children and teens either previously immunized with or na\u00efve to 7-valent pneumococcal conjugate vaccine. Presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases, Igua\u00e7u Falls, Brazil, March 11\u201315, 2012. Available online at: http:\/\/www2.kenes.com\/ISPPD\/Scientific\/Documents\/FinalAbstractbook.pdf . Accessed 12 August 2014"},{"key":"2208_CR87","unstructured":"Bundesministerium f\u00fcr Gesundheit (2014) \u00d6sterreichischer Impfplan 2014. Bundesministerium f\u00fcr Gesundheit. Available online at: http:\/\/bmg.gv.at\/home\/Schwerpunkte\/Praevention\/Impfen\/Oesterreichischer_Impfplan_2014 . Accessed 12 August 2014"},{"key":"2208_CR88","unstructured":"Conseil Sup\u00e9rieur de la Sant\u00e9 (2013) Vaccination antipneumococcique: vaccination de l\u2019adulte (r\u00e9vision 13). Conseil Sup\u00e9rieur de la Sant\u00e9. Available online at: http:\/\/www.health.belgium.be\/filestore\/19086989_FR\/vaccination%20fiche%20contre%20pneumoccoque.pdf . Accessed 12 August 2014"},{"key":"2208_CR89","unstructured":"Statens Serum Institut (2012) Pneumococcal vaccination of persons at increased risk of invasive pneumococcal disease. EPI-NEWS. Available online at: http:\/\/www.ssi.dk\/English\/News\/EPI-NEWS\/2012\/No%2051b%20-%202012.aspx . Accessed 12 August 2014"},{"key":"2208_CR90","unstructured":"Terveyden ja hyvinvoinnin laitos (2013) Pneumokokkirokotukset. Rokottajan k\u00e4sikirja. Available online at: http:\/\/www.thl.fi\/fi_FI\/web\/rokottajankasikirja-fi\/pneumokokkirokotukset . Accessed 12 August 2014"},{"key":"2208_CR91","unstructured":"Haut Conseil de la Sant\u00e9 Publique (2013) Infections invasives \u00e0 pneumocoque : recommandations vaccinales pour les personnes \u00e0 risque. Haut Conseil de la Sant\u00e9 Publique. Available online at: http:\/\/www.hcsp.fr\/Explore.cgi\/avisrapportsdomaine?clefr=355 . Accessed 12 August 2014"},{"key":"2208_CR92","unstructured":"Richtlinie Schutzimpfungs-Richtlinie Stand (2013) 20. Dezember 2013 des Gemeinsamen Bundesausschusses \u00fcber Schutzimpfungen nach \u00a7 20d Abs. 1 SGB V. Gemeinersamer Bundesausschuss. Available online at: https:\/\/www.g-ba.de\/downloads\/62-492-813\/SI-RL_2013-10-01.pdf . Accessed 12 August 2014"},{"key":"2208_CR93","unstructured":"\u0394\u03b9\u03b5\u03cd\u03b8\u03c5\u03bd\u03c3\u03b7 \u0394\u03b7\u03bc\u03cc\u03c3\u03b9\u03b1\u03c2 \u03a5\u03b3\u03b9\u03b5\u03b9\u03bd\u03ae\u03c2 \u03c4\u03bf\u03c5 \u03a5\u03c0\u03bf\u03c5\u03c1\u03b3\u03b5\u03af\u03bf\u03c5 \u03a5\u03b3\u03b5\u03af\u03b1\u03c2 \u03ba\u03b1\u03b9 \u039a\u03bf\u03b9\u03bd\u03c9\u03bd\u03b9\u03ba\u03ae\u03c2 \u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03b3\u03b3\u03cd\u03b7\u03c2. \u0395\u03b8\u03bd\u03b9\u03ba\u03ae \u0395\u03c0\u03b9\u03c4\u03c1\u03bf\u03c0\u03ae \u0395\u03bc\u03b2\u03bf\u03bb\u03b9\u03b1\u03c3\u03bc\u03ce\u03bd. \u03a0\u03c1\u03cc\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1 \u0395\u03bc\u03b2\u03bf\u03bb\u03b9\u03b1\u03c3\u03bc\u03ce\u03bd \u0395\u03bd\u03b7\u03bb\u03af\u03ba\u03c9\u03bd (\u0391\u03b8\u03ae\u03bd\u03b1 21\/12\/2011, \u0391\u03c1 \u03a0\u03c1\u03c9\u03c4. \u03a51\/\u0393.\u03a0.\u03bf\u03b9\u03ba.140958) Available: http:\/\/static.diavgeia.gov.gr\/doc\/45%CE%A8%CE%A8%CE%98-2%CE%98%CE%9C . Accessed 12 August 2014"},{"key":"2208_CR94","unstructured":"National Immunisation Advisory Committee of the Royal College of Physicians of Ireland (2013) Immunisation Guidelines for Ireland, 2013 Edition (updated June 2014). Chapter 16: pneumococcal infection. Health Service Executive. Available online at: http:\/\/www.immunisation.ie\/en\/HealthcareProfessionals\/ImmunisationGuidelines\/ . Accessed 12 August 2014"},{"key":"2208_CR95","unstructured":"Conseil Superieur D\u2019hydiene (2008) Recommandations pour la vaccination contre le pneumocoque par le vaccin 23valent. Grand Duch\u00e9 de Luxembourg. Available online at: http:\/\/www.sante.public.lu\/fr\/recommandations\/conseil-maladies-infectieuses\/pneumonie\/recommandations-vaccinations-2008\/pneumonie-recommandations-vaccinatin-pneumocoque-23valent-2008.pdf . Accessed 12 August 2014"},{"key":"2208_CR96","unstructured":"Nasjonalt folkehelseinstitutt (2013) Anbefalinger for bruk av pneumokokkvaksine utenfor barnevaksinasjonsprogram i Norge. Nasjonalt folkehelseinstitutt. Available online at: http:\/\/www.fhi.no\/dokumenter\/14a5077fef.pdf . Accessed 12 August 2014"},{"key":"2208_CR97","unstructured":"Helse- og omsorgsdepartementet (2007) Forskrift om st\u00f8nad til dekning av utgifter til viktige legemidler mv. (bl\u00e5reseptforskriften). Lovdata. Available online at: http:\/\/www.lovdata.no\/for\/sf\/ho\/xo-20070628-0814.html . Accessed 12 August 2014"},{"key":"2208_CR98","unstructured":"Socialstyrelsen (1994) SOSFS 1994:26: Socialstyrelsens allm\u00e4nna r\u00e5d; Vaccination mot pneumokocker. Socialstyrelsen. Available online at: http:\/\/www.socialstyrelsen.se\/publikationer1994\/1994-10-26 . Accessed 12 August 2014"},{"key":"2208_CR99","unstructured":"Public Health England (2013) Pneumococcal: the green book, chapter 25. gov.uk. Available online at: https:\/\/www.gov.uk\/government\/publications\/pneumococcal-the-green-book-chapter-25 . Accessed 12 August 2014"},{"key":"2208_CR100","unstructured":"Obenga G, Mahlaoul N, Launay O (2009) Recommandations vaccinales chez les patients atteints de d\u00e9ficit immunitaire h\u00e9r\u00e9ditaire. CEREDIH. Available online at: http:\/\/www.ceredih.fr\/documents\/Recos_Vaccins_20091113.pdf . Accessed 12 August 2014"},{"key":"2208_CR101","unstructured":"Dominguez V, Arrazola P, Campins M, Chamorro J, de Diego J, Fenoli A, Gil A, Mollar J, Quintas C, Torres Lana A (2012) Recomendaciones de vacunaci\u00f3n antineumoc\u00f3cica en el adulto por indicaci\u00f3n m\u00e9dica. SEMPSPH. Available online at: http:\/\/www.sempsph.com\/images\/stories\/recursos\/pdf\/protocolos\/2012\/Recom_Vac_Antineumococica_SEMPSPH.pdf . Accessed 12 August 2014"},{"key":"2208_CR102","unstructured":"Jim\u00e9nez R, Solano R, Riesco M, Altet G, Signes-Costa M, Lorza B, de Granda O, Ramos P, de Higes M, Plaza V, Celdr\u00e1n G, Mart\u00ednez M, Santacruz S (2012) Recomendaciones para la vacunaci\u00f3n neumoc\u00f3cica en fumadores. Prev Tab. Available online at: http:\/\/issuu.com\/separ\/docs\/prev_tab_14-4?e=3049452\/1121963 . Accessed 12 August 2014"},{"key":"2208_CR103","unstructured":"Engelhardt M, Eber SW, Germing U, Heimpel H, Kern W, Schmugge M, Haas PS, Minkov M, Theilacker C (2013) Pr\u00e4vention von Infektionen und Thrombosen nach Splenektomie oder funktioneller Asplenie. DGHO Onkopedia. Available online at: http:\/\/www.dgho-onkopedia.de\/de\/onkopedia\/leitlinien\/praevention-von-infektionen-und-thrombosen-nach\/pra-vention-von-infektionen-und-thrombosen-nach.pdf . Accessed 12 August 2014"},{"key":"2208_CR104","unstructured":"Robert Koch Institut (2013) Impfungen bei Asplenie (Entfernung der Milz oder Ausfall der Organfunktion). Robert Koch Institut. Available online at: http:\/\/www.rki.de\/SharedDocs\/FAQ\/Impfen\/AllgFr_ImpfGesundheitsschaden\/FAQ01.html?nn=2391120 . Accessed 12 August 2014"},{"key":"2208_CR105","unstructured":"Societ\u00e0 scientifiche dell\u2019Igiene pubblica, Federazione Italiana Medici Pediatri, and Federazione Italiana Medici di Medicina Generale (2012) Calendario Vaccinale per la Vita. Societ\u00e0 scientifiche dell\u2019Igiene pubblica. Available online at: http:\/\/www.societaitalianaigiene.org\/site\/new\/images\/docs\/calendariovaccinale\/2012\/cvplv.pdf . Accessed 12 August 2014"},{"key":"2208_CR106","unstructured":"World Health Organization (WHO) (2005) Vaccine introduction guidelines. Adding a vaccine to a national immunization programme: decision and implementation. WHO. Available online at: http:\/\/whqlibdoc.who.int\/hq\/2005\/WHO_IVB_05.18.pdf Accessed 12 August 2014"},{"key":"2208_CR107","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4161\/hv.23268","volume":"9","author":"S Boccalini","year":"2013","unstructured":"Boccalini S, Bechini A, Levi M, Tiscione E, Gasparini R, Bonanni P (2013) Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Hum Vaccin Immunother 9:699\u2013706","journal-title":"Hum Vaccin Immunother"},{"key":"2208_CR108","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2191-1991-2-4","volume":"2","author":"A Kuhlmann","year":"2012","unstructured":"Kuhlmann A, Theidel U, Pletz MW, von der Schulenburg JM (2012) Potential cost-effectiveness and benefit\u2013cost ratios of adult pneumococcal vaccination in Germany. Health Econ Rev 2:4","journal-title":"Health Econ Rev"},{"key":"2208_CR109","first-page":"378","volume":"66","author":"E Hak","year":"2008","unstructured":"Hak E, Grobbee DE, Sanders EA, Verheij TJ, Bolkenbaas M, Huijts SM, Gruber WC, Tansey S, McDonough A, Thoma B, Patterson S, van Alphen AJ, Bonten MJ (2008) Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 66:378\u2013383","journal-title":"Neth J Med"},{"key":"2208_CR110","unstructured":"clinicaltrials.gov (2014) Study Evaluating the Efficacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults (CAPITA). clinicaltrials.gov. Available online at: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00744263?term=Prevenar+13&rank=92 . Accessed 12 August 2014"},{"key":"2208_CR111","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12325-013-0007-6","volume":"30","author":"TT Myint","year":"2013","unstructured":"Myint TT, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D, Sprenger R, Bonnet E (2013) The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther 30:127\u2013151","journal-title":"Adv Ther"},{"key":"2208_CR112","unstructured":"Myint TT, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D, Sprenger R, Bonnet E (2012) The impact of 7-valent pneumococcal conjugate vaccine (PCV7) on pneumonia and mortality: a literature review. Presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases, Igua\u00e7u Falls, Brazil, March 11\u201315, 2012. Available online at: http:\/\/www2.kenes.com\/ISPPD\/Scientific\/Documents\/FinalAbstractbook.pdf . Accessed 12 August 2014"},{"key":"2208_CR113","unstructured":"Moore M, Link-Gelles R, Farley MM, Schaffner W, Thomas A, Reingold A, Harrison L, Lexau C, Zansky S, Petit S, Gershman K, Scherzinger K, MacInnes K, Beall B, Whitney C (2012) Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, U.S., 2010\u201311. Presented at IDWeek 2012, San Diego, CA, October 17\u201321, 2012. Available online at: https:\/\/idsa.confex.com\/idsa\/2012\/webprogram\/Paper36569.html . Accessed 12 August 2014"},{"key":"2208_CR114","unstructured":"Picazo J, Ruiz-Contreras J, Casado-Flores J, Giangaspro E, Garc\u00eda-de Miguel MJ, Hern\u00e1ndez-Sampelayo T, Otheo E, M\u00e9ndez C (2012) First impact data of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease in children in Madrid, 2010\u20132011 (Heracles study). Presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases, Igua\u00e7u Falls, Brazil, March 11\u201315, 2012. Available online at: http:\/\/www2.kenes.com\/ISPPD\/Scientific\/Documents\/FinalAbstractbook.pdf . Accessed 12 August 2014"},{"key":"2208_CR115","unstructured":"Georgakopoulou T, Menegas D, Tzanakaki G, Pipa E, Vernardaki A, Mavraganis P, Theodoridou M., Kremastinou J (2012) Epidemiology of bacterial meningitis in Greece, in the era of conjugate vaccines: a 7 years review 2005\u20132011. Presented at the 52nd ICAAC, San Francisco, CA, USA, September 9\u201312 2012. Available online at: http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=d201a978-86b7-4126-b4eb-dce82709451f&cKey=fd9b920f-2dad-4c23-9dba-3f0f20b33da8&mKey=%7b6B114A1D-85A4-4054-A83B-04D8B9B8749F%7d . Accessed 12 August 2014"},{"key":"2208_CR116","unstructured":"Pardo-Sanchez F, Garc\u00eda-Magan C, Martinon-Torres N, Guinda Gimenez M, M\u00e9ndez-Lage S, Seoane-Pilado MT, Pertega-Diaz S, Martinon-Torres F (2012) Early impact of a universal immunization program with the 13-valent conjugate pneumococcal vaccine in Santiago de Compostela area (Spain). Abstract 588. Presented at the 30th Annual Meeting of the European Society for Paediatric Infectious Diseases, Thessaloniki, Greece, May 8\u201312 2012. Available online at: http:\/\/espid.kenes.com\/Documents\/ESPID2012%20ABSTRACTS.pdf . Accessed 12 August 2014"},{"key":"2208_CR117","unstructured":"Pichichero M, Casey JR, Center K, Chen L, Mathur P, Durham K, Gurtman A, Scott DA (2012) Efficacy of PCV13 in prevention of AOM and NP colonization in children: first year of data from the US. Presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases, Igua\u00e7u Falls, Brazil, March 11\u201315, 2012. Available online at: http:\/\/www2.kenes.com\/ISPPD\/Scientific\/Documents\/FinalAbstractbook.pdf . Accessed 12 August 2014"}],"updated-by":[{"DOI":"10.1007\/s10096-014-2258-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,10,18]],"date-time":"2014-10-18T00:00:00Z","timestamp":1413590400000}}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-014-2208-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-014-2208-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-014-2208-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-014-2208-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T10:56:01Z","timestamp":1717498561000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-014-2208-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,23]]},"references-count":117,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["2208"],"URL":"https:\/\/doi.org\/10.1007\/s10096-014-2208-6","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,23]]}}}